Alamar Biosciences has partnered with leading U.S. universities to launch a nationwide proteomics study analyzing around 21,000 plasma samples from 10,000 Alzheimer's and related dementia patients. Using its NULISAseq™ Neuro 220 test kit, the project aims to accelerate discovery and validation of blood-based biomarkers for neurodegenerative diseases. Data generated will be openly accessible through the National Alzheimer’s Coordinating Center, supporting AI-driven research and a national data competition. This initiative could significantly enhance understanding of disease mechanisms and improve diagnosis and treatment development.
The 2026 SANS AI Survey reveals rapid AI adoption in cybersecurity, with 78% of organizations using AI, up from 50% last year. However, governance structures and formal audit frameworks have not kept pace, leading to increased AI-related failures in ...
The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a 10.5% CAGR from 2026 to 2036, driven by rising cancer incidence and new immunotherapy launches. Key emerging therapies from companies like Johnson & Johnson, BioNTech,...
Noble Capital Markets has initiated equity research coverage on VivoPower PLC, assigning an Outperform rating and setting a price target of $10. VivoPower is a B Corp-certified global developer of powered land and data center infrastructure for AI ap...
Alamar Biosciences has partnered with top U.S. research universities to start a nationwide proteomics project using its NULISAseq™ Neuro 220 panel. The study will analyze about 21,000 plasma samples from 10,000 Alzheimer's and related dementia partic...
At its July 9, 2026 annual meeting, BIGG Digital Assets Inc. shareholders approved all key proposals, including the election of the full board of directors, re-appointment of KPMG as auditor, and renewal of the Omnibus Equity Incentive Plan. CEO Fras...
